KR20120100913A - 아세틸콜린 수용체에 관련된 질환의 치료를 위한 축합 아진 - 유도체 - Google Patents

아세틸콜린 수용체에 관련된 질환의 치료를 위한 축합 아진 - 유도체 Download PDF

Info

Publication number
KR20120100913A
KR20120100913A KR1020127009340A KR20127009340A KR20120100913A KR 20120100913 A KR20120100913 A KR 20120100913A KR 1020127009340 A KR1020127009340 A KR 1020127009340A KR 20127009340 A KR20127009340 A KR 20127009340A KR 20120100913 A KR20120100913 A KR 20120100913A
Authority
KR
South Korea
Prior art keywords
diazabicyclo
methyl
nonan
alkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127009340A
Other languages
English (en)
Korean (ko)
Inventor
폴 데이비드 랫클리프
토마스 러셀 클락슨
피오나 제레미아
존 킨네어드 퍼거슨 맥린
Original Assignee
엠에스데 오쓰 베.베.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엠에스데 오쓰 베.베. filed Critical 엠에스데 오쓰 베.베.
Publication of KR20120100913A publication Critical patent/KR20120100913A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020127009340A 2009-10-13 2010-10-11 아세틸콜린 수용체에 관련된 질환의 치료를 위한 축합 아진 - 유도체 Withdrawn KR20120100913A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25110109P 2009-10-13 2009-10-13
EP09172872 2009-10-13
EP09172872.5 2009-10-13
US61/251,101 2009-10-13

Publications (1)

Publication Number Publication Date
KR20120100913A true KR20120100913A (ko) 2012-09-12

Family

ID=42040651

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127009340A Withdrawn KR20120100913A (ko) 2009-10-13 2010-10-11 아세틸콜린 수용체에 관련된 질환의 치료를 위한 축합 아진 - 유도체

Country Status (12)

Country Link
US (1) US8841289B2 (https=)
EP (1) EP2488520B1 (https=)
JP (1) JP2013507417A (https=)
KR (1) KR20120100913A (https=)
CN (1) CN102666540A (https=)
AU (1) AU2010305825A1 (https=)
BR (1) BR112012008518A2 (https=)
CA (1) CA2776835A1 (https=)
IN (1) IN2012DN02968A (https=)
MX (1) MX2012004289A (https=)
RU (1) RU2012119488A (https=)
WO (1) WO2011045258A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336268B (es) 2011-07-29 2016-01-13 Toyama Chemical Co Ltd Compuesto de amidina o sal del mismo.
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP2852382A1 (en) * 2012-05-22 2015-04-01 King Abdullah University Of Science And Technology Combination comprising parthenolide for use in the treatment of alzheimer's disease and other neurodegenerative disorders
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
EP3623371A1 (en) 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
US9840491B2 (en) 2015-02-05 2017-12-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
EP3253765A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
US9938300B2 (en) 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
CN106146410B (zh) * 2015-04-03 2018-10-12 中南大学 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
CN106279211B (zh) 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
CN107847494A (zh) 2015-06-10 2018-03-27 阿考温特科学股份有限公司 作为α7‑烟碱乙酰胆碱受体激动剂的氨基苯并异噁唑化合物
JP2018523707A (ja) 2015-08-12 2018-08-23 アクソバント サイエンシズ ゲーエムベーハー α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物
JP7071917B2 (ja) 2015-12-09 2022-05-19 カデント セラピューティクス，インコーポレーテッド ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用
EP4006038A1 (en) 2015-12-09 2022-06-01 Cadent Therapeutics, Inc. Thienopyrimidinone nmda receptor modulators and uses thereof
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
BR112020026637A2 (pt) * 2018-06-27 2021-03-30 Reborna Biosciences, Inc. Agente profilático ou terapêutico para atrofia muscular espinhal
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
KR20210039368A (ko) 2018-07-26 2021-04-09 도메인 테라퓨틱스 치환된 퀴나졸리논 유도체 및 mGluR4의 양성 알로스테릭 조절인자로서의 이의 용도
AR115905A1 (es) 2018-08-03 2021-03-10 Cadent Therapeutics Inc 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1-il)-2-oxoetil)-3,7-dihidro-4h-pirrolo[2,3-d]pirimidin-4-ona como modulador de los receptores de nmda
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
US20230150978A1 (en) 2020-03-30 2023-05-18 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN112898290B (zh) * 2021-01-29 2022-08-05 中南大学 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2025176185A1 (zh) * 2024-02-23 2025-08-28 海思科医药集团股份有限公司 一种braf抑制剂的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
CA2444598A1 (en) * 2001-04-20 2003-10-31 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of gsk-3
US7148236B2 (en) * 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
CA2615577C (en) * 2005-07-26 2014-09-09 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
CN101600698B (zh) 2006-09-11 2012-01-11 欧加农股份有限公司;药典有限责任公司 喹唑啉酮和异喹啉酮乙酰胺衍生物
MY148902A (en) * 2006-12-27 2013-06-14 Sanofi Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
JP2010229035A (ja) * 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
EP2209783B8 (en) * 2007-11-14 2016-06-01 Saniona A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use
CN101960691B (zh) 2008-02-29 2013-04-24 核心技术国际有限公司 电池组的充电装置和电池组的品质判断装置

Also Published As

Publication number Publication date
BR112012008518A2 (pt) 2016-04-05
IN2012DN02968A (https=) 2015-07-31
CN102666540A (zh) 2012-09-12
MX2012004289A (es) 2012-06-12
EP2488520A1 (en) 2012-08-22
RU2012119488A (ru) 2013-11-20
EP2488520B1 (en) 2015-09-02
CA2776835A1 (en) 2011-04-21
AU2010305825A1 (en) 2012-04-19
US20120208796A1 (en) 2012-08-16
WO2011045258A1 (en) 2011-04-21
US8841289B2 (en) 2014-09-23
JP2013507417A (ja) 2013-03-04

Similar Documents

Publication Publication Date Title
EP2488520B1 (en) Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor
CN113061132B (zh) 一类稠环内酰胺类化合物、制备方法和用途
CN116332948A (zh) 一种含氮四环化合物及其制备方法和药用用途
DK2300478T3 (en) 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-ONDERIVATIVER and their use as modulators PDE9A.
JP6673920B2 (ja) Ｐａｒｇ阻害化合物
EP2057141B1 (en) Pyrimidone compounds as gsk-3 inhibitors
JP6800885B2 (ja) イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用
WO2014060112A1 (en) Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
AU2022420827A1 (en) Compounds and use thereof as hdac6 inhibitors
CA2699384A1 (en) Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists
JP7801084B2 (ja) Ｅｇｆｒ阻害剤としてのインドリン化合物及び誘導体
JP2022547729A (ja) 自己免疫疾患を治療するためのピペリジニルアミン化合物
RS63661B1 (sr) Piridopirimidini kao inhibitori histaminskog h4-receptora
WO2009043884A1 (en) Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors
WO2024261329A1 (en) Heteroaryl-amine compounds and use thereof as hdac6 inhibitors
MX2010011136A (es) Derivados de pirrolo [2,3-d] pirimidin-2-il-amina como inhibidores pkc-theta.
WO2026027696A1 (en) Thiomethyl carbonyl compounds and use thereof as hdac6 inhibitors
AU2006314136A1 (en) Substituted bicyclic pyrimidone derivatives
HK1149549B (en) 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120412

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20130530

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid